At the time of presentation, most ovarian cancers are no longer dependent on single genetic determinants for growth and/or survival. Targeted therapies used as single agents will not work in this disease and thus second site lethality screens will help identify critical pathways to target in combination with novel biologics. Our objectives are to take genes obtained through our synthetic lethal siRNA screens, and use them to map the sensitization network for targeted therapeutics relevant to EOC, and design meaningful combinations of siRNAs with drugs, or drugs with drugs, that can be rapidly translated to the clinic. We have used RNAi approaches to identify candidates that selectively enhance killing by the Src-targeting agent, dasatinib (also known as BMS-354825, Sprycel"). Mapping the pattern of hits back to the network map revealed suggestive clusters of closely interacting proteins, implying identification of key survival nodes. The three Aims proposed will systematically develop our preliminary studies to identify productive targets of co-inhibition, with the ultimate goal of identifying new drug combinations that will greatly enhance the treatment of women with EOC. Hence, Aims 1 &2 are designed to apply a series of in vitro filters to help prioritize selection of the optimal combination of proteins to target using clinically relevant therapies in animal models. Specifically, Aim 1 will refine our high-value list of validated dasatinib-sensitizing siRNAs by screening a set of EOC cell lines and primary cultures generated from ascites obtained from patient with ovarian cancer and cluster these sensitizing genes into coordinated groups based on network modeling, in vitro drug-drug synergy studies, and functional studies to be completed in this Aim.
In Aim 2, we will explore the expression patterns of proteins and transcripts for the refined hits identified in Aim 1 in patient samples to assess their pathological and clinical relevance.
In Aim 3, for the highest priority hits we will conduct drug pharmacokinetic and toxicity studies in animals using drug-drug combinations evaluated at various ratios as dictated by our in vitro synergy data. We will identify optimal dosage regimens and evaluate their therapeutic efficacy in xenograft animal models. For hits lacking clinically developed agents, we will perform siRNA-drug combinations in the animal models. We believe that this cutting-edge approach will yield a paradigm that can subsequently be applied for multiple therapeutic applications.

Public Health Relevance

The studies proposed offer an unprecedented opportunity to employ a functional approach in designing combination therapies that can be applied to improve ovarian cancer treatment outcomes with contemporary agents such as dasatinib, with or without the front line chemotherapeutic agents, platinum and paclitaxel. They will also provide valuable preclinical resources regarding drug safety and dosage regimen to help design future clinical trials with combination therapy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA140323-04
Application #
8444503
Study Section
Basic Mechanisms of Cancer Therapeutics Study Section (BMCT)
Program Officer
Arya, Suresh
Project Start
2010-04-01
Project End
2015-01-31
Budget Start
2013-02-01
Budget End
2014-01-31
Support Year
4
Fiscal Year
2013
Total Cost
$305,447
Indirect Cost
$101,816
Name
University of Kansas
Department
Pathology
Type
Schools of Medicine
DUNS #
016060860
City
Kansas City
State
KS
Country
United States
Zip Code
66160
Sethi, Geetika; Kwon, Youngjoo; Burkhalter, Rebecca J et al. (2015) PTN signaling: Components and mechanistic insights in human ovarian cancer. Mol Carcinog 54:1772-85
Peterlongo, Paolo; Chang-Claude, Jenny; Moysich, Kirsten B et al. (2015) Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev 24:308-16
Fridley, Brooke L; Koestler, Devin C; Koeslter, Devin C et al. (2014) Individualizing care for ovarian cancer patients using big data. J Natl Cancer Inst 106:
Purrington, Kristen S; Slager, Susan; Eccles, Diana et al. (2014) Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer. Carcinogenesis 35:1012-9
Osorio, Ana; Milne, Roger L; Kuchenbaecker, Karoline et al. (2014) DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. PLoS Genet 10:e1004256
Do, T-V; Xiao, F; Bickel, L E et al. (2014) Aurora kinase A mediates epithelial ovarian cancer cell migration and adhesion. Oncogene 33:539-49
He, Mei; Crow, Jennifer; Roth, Marc et al. (2014) Integrated immunoisolation and protein analysis of circulating exosomes using microfluidic technology. Lab Chip 14:3773-80
Price, Jessica C; Pollock, Lana M; Rudd, Meghan L et al. (2014) Sequencing of candidate chromosome instability genes in endometrial cancers reveals somatic mutations in ESCO1, CHTF18, and MRE11A. PLoS One 8:e63313
Rudd, Meghan L; Mohamed, Hassan; Price, Jessica C et al. (2014) Mutational analysis of the tyrosine kinome in serous and clear cell endometrial cancer uncovers rare somatic mutations in TNK2 and DDR1. BMC Cancer 14:884
Yew, Kok-Hooi; Crow, Jennifer; Hirst, Jeff et al. (2013) Epimorphin-induced MET sensitizes ovarian cancer cells to platinum. PLoS One 8:e72637

Showing the most recent 10 out of 34 publications